Gsa Capital Partners LLP Genprex, Inc. Transaction History

Gsa Capital Partners LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$1.28 - $2.31 $158,231 - $285,557	-123,618 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.82 - $3.5 $328,120 - $631,001	-180,286 Reduced 59.32%	123,618 $279,000
Q4 2021 Feb 14, 2022	SELL	$1.21 - $2.7 $127,945 - $285,498	-105,740 Reduced 25.81%	303,904 $398,000
Q3 2021 Nov 12, 2021	BUY	$2.59 - $3.36 $1.06 Million - $1.38 Million	409,644 New	409,644 $1.1 Million

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $80.2M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.